Dr. Anat Ben-Yaacov holds a Ph.D degree in Biology from the Hebrew University of Jerusalem. Her PhD thesis, under the supervision of Prof. Yael Stern-Bach, focuses on glutamate receptors, the most abundant receptors in the brain- particularly these of the AMPA type- and their regulation by auxiliary proteins. This was achieved through the identification of the regulatory domains and protein-protein interfaces, employing methods of electrophysiology, biochemistry, and microscopy. Anat has also completed her post-doctoral research in the Cancer Research Center in Sheba Hospital and Tel-Aviv University. Her research topic dealt primarily with RNA modifications and regulation of gene expression. Anat joined IMBM in August 2019. At IMBM she provides biological input to various research projects. She has been mainly involved in the study of bacterial sepsis and, at present, of viral sepsis and prostate cancer.
Scientific activity in 2021
In 2021, Anat has been involved in the COVID-19 project, mainly in the development of the initial verbal model, describing the dynamics to be included in the mathematical model. Anat has been involved in selecting for the model the components of the immune system, and their dynamic interactions, based upon extensive literature research. These efforts resulted in Covid-19 model Ver. 1. Anat also has been involved in the preparation and processing of a large patient Real World cohort obtained from Sheba Medical Center, to be studied in IMBM, as well as in analyzing the dataset of hormone-sensitive prostate cancer patients obtained from the Mayo Clinic Rochester, USA, in 2016.
Scientific activity in 2022
In 2022, Anat will continue to take part both in the COVID-19 and in the prostate cancer projects. In the COVID-19 project, she will work on the verbal model, Covid-19 Ver. 2., adjusting, adapting, and extending the model according to up-to-date literature knowledge, patients’ data and results of mathematical and statistical analyses at IMBM. A new version of the verbal-mathematical mechanistic model will then be designed and studied by the COVID-19 team, and results will be published in professional journals.
In the prostate cancer project, Anat will contribute to large new patient dataset integration and analysis, as well as literature research, in both the hormone-sensitive and the castrate-resistant arms of the prostate cancer disease (HSPC and mCRPC, respectively). This will aid in developing a dynamical mathematical model of the disease with or without therapy, eventually enabling the personalization of the model and prediction of both the time to crucial clinical events and the optimal drug therapy for the individual patient.
- Gillis A, Ben Yaacov A, Agur Z. A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker. Frontiers in Immunology (2021), https://doi.org/10.3389/fimmu.2021.616881.
- Ben-Yaacov et al., Molecular Mechanism of AMPA Receptor Modulation by TARP/Stargazin, Neuron (2017), http://dx.doi.org/10.1016/j.neuron.2017.01.032.